Gene products of chromosome 11q and their association with CCND1gene amplification and tamoxifen resistance in premenopausal breast cancer
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1465-542X
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Gene products of chromosome 11q and their association with CCND1gene amplification and tamoxifen resistance in premenopausal breast cancer ; volume:10 ; number:5 ; day:29 ; month:9 ; year:2008 ; pages:1-14 ; date:10.2008
Breast cancer research ; 10, Heft 5 (29.9.2008), 1-14, 10.2008
- Creator
-
Lundgren, Katja
- Contributor
-
Holm, Karolina
Nordenskjöld, Bo
Borg, Åke
Landberg, Göran
SpringerLink (Online service)
- DOI
-
10.1186/bcr2150
- URN
-
urn:nbn:de:1111-201603241756
- Rights
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:58 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Lundgren, Katja
- Holm, Karolina
- Nordenskjöld, Bo
- Borg, Åke
- Landberg, Göran
- SpringerLink (Online service)
Other Objects (12)
Tumor-specific HMG-CoA reductase expression in primary premenopausal breast cancer predicts response to tamoxifen
Tamoxifen or aromatase inhibitors with ovarian function suppression in pre-menopausal stage I-III lobular breast cancer
Prediction of menstrual recovery patterns in premenopausal women with breast cancer taking tamoxifen after chemotherapy: an ASTRRA Substudy
Mammographic density change in a cohort of premenopausal women receiving tamoxifen for breast cancer prevention over 5 years
Tamoxifen-predictive value of gene expression signatures in premenopausal breast cancer: data from the randomized SBII:2 trial
Tamoxifen
Formation and Effects of Transformation Products during the Ozonation of Tamoxifen
A prospective, randomized study of Toremifene vs. tamoxifen for the treatment of premenopausal breast cancer: safety and genital symptom analysis
Over-elongation of centrioles in cancer promotes centriole amplification and chromosome missegregation
A randomized phase II presurgical trial of weekly low-dose tamoxifen versus raloxifene versus placebo in premenopausal women with estrogen receptor-positive breast cancer
Tumour-infiltrating lymphocytes as a prognostic and tamoxifen predictive marker in premenopausal breast cancer: data from a randomised trial with long-term follow-up
Morphologische Endometriumveränderungen unter Tamoxifen
Tumor-specific HMG-CoA reductase expression in primary premenopausal breast cancer predicts response to tamoxifen
Tamoxifen or aromatase inhibitors with ovarian function suppression in pre-menopausal stage I-III lobular breast cancer
Prediction of menstrual recovery patterns in premenopausal women with breast cancer taking tamoxifen after chemotherapy: an ASTRRA Substudy
Mammographic density change in a cohort of premenopausal women receiving tamoxifen for breast cancer prevention over 5 years
Tamoxifen-predictive value of gene expression signatures in premenopausal breast cancer: data from the randomized SBII:2 trial
Tamoxifen
Formation and Effects of Transformation Products during the Ozonation of Tamoxifen
A prospective, randomized study of Toremifene vs. tamoxifen for the treatment of premenopausal breast cancer: safety and genital symptom analysis
Over-elongation of centrioles in cancer promotes centriole amplification and chromosome missegregation
A randomized phase II presurgical trial of weekly low-dose tamoxifen versus raloxifene versus placebo in premenopausal women with estrogen receptor-positive breast cancer
Tumour-infiltrating lymphocytes as a prognostic and tamoxifen predictive marker in premenopausal breast cancer: data from a randomised trial with long-term follow-up
Morphologische Endometriumveränderungen unter Tamoxifen
Tumor-specific HMG-CoA reductase expression in primary premenopausal breast cancer predicts response to tamoxifen
Tamoxifen or aromatase inhibitors with ovarian function suppression in pre-menopausal stage I-III lobular breast cancer
Prediction of menstrual recovery patterns in premenopausal women with breast cancer taking tamoxifen after chemotherapy: an ASTRRA Substudy
Mammographic density change in a cohort of premenopausal women receiving tamoxifen for breast cancer prevention over 5 years
Tamoxifen-predictive value of gene expression signatures in premenopausal breast cancer: data from the randomized SBII:2 trial
Tamoxifen
Formation and Effects of Transformation Products during the Ozonation of Tamoxifen
A prospective, randomized study of Toremifene vs. tamoxifen for the treatment of premenopausal breast cancer: safety and genital symptom analysis
Over-elongation of centrioles in cancer promotes centriole amplification and chromosome missegregation
A randomized phase II presurgical trial of weekly low-dose tamoxifen versus raloxifene versus placebo in premenopausal women with estrogen receptor-positive breast cancer
Tumour-infiltrating lymphocytes as a prognostic and tamoxifen predictive marker in premenopausal breast cancer: data from a randomised trial with long-term follow-up